Figure 3From: Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients(A) OS and (B) EFS of VAD-chemosensitive (green line) and less chemosensitive (blue line) patients, showing comparable OS and EFS in VAD-chemosensitive and less chemosensitive patients.Back to article page